logo linkedin

Arti­cles:

  1. PUDDU P.E., SALLE L., GER­ARD J.L., ROUET R., DUCROQ J. (2012). IKs block­ade in bor­der zone arrhyth­mias from guinea-​pig ven­tric­u­lar myocardium sub­mit­ted to sim­u­lated ischemia and reper­fu­sion. Fund. Clin. Phar­ma­col. 26 (4) : 44553. link

  1. PUDDU P.E., LEGRAND J.C., SALLE L., ROUET R., DUCROQ J. (2011). IKr vs. IKs block­ade and arrhyth­mo­genic­ity in nor­moxic rab­bit Purk­inje fibers: does it really makes the dif­fer­ence ? Fund. Clin. Phar­ma­col. 25 (3) : 30412. link

  1. DUCROQ J., MOHA OU MAATI H., GUIL­BOT S., DILLY S., LAEM­MEL E., PONS-​HIMBERT C., FAIVRE J.F., BOIS P., STUCKER O., LE GRAND M. (2010). Dexra­zox­ane pro­tects the heart from acute doxorubicin-​induced QT pro­lon­ga­tion : a key role for IKs. Br. J. Phar­ma­col.159 : 93101. link

  1. DUCROQ J., PRINT­EMPS R., GUIL­BOT S., GARDETTE J, SAL­VE­TAT C., LE GRAND M. (2007). Action poten­tial exper­i­ments com­plete hERG assay and QT-​interval mea­sure­ments in car­diac pre­clin­i­cal stud­ies. J. Phar­ma­col Tox­i­col Meth­ods.56: 15970. link

  1. DUCROQ J., ROUET R., SALLE L., PUDDU P.E., REPESSE Y., GHADAN­FAR M., DUCOURET P., GER­ARD J.L. (2006). Class III effects of dofetilide and arrhyth­mias are mod­u­lated by [K+]o in an in vitro model of simulated-​ischemia and reper­fu­sion in guinea-​pig ven­tric­u­lar myocardium. Eur. J. Phar­ma­col.532: 27989. link

  1. DUCROQ J., ROUET R., PUDDU P.E., SALLE L., TABOUREL C., DUCOURET P., GER­ARD J.L. (2005). Elec­tro­phys­i­o­log­i­cal effects of azim­ilide in an in vitro model of simulated-​ischemia and reper­fu­sion in guinea-​pig ven­tric­u­lar myocardium. Eur. J. Phar­ma­col.518: 16574. link

  1. DUCROQ J., PRINT­EMPS R., LE GRAND M. (2005). Addi­tive effects of ziprasi­done and D,L-sotalol on the action poten­tial in rab­bit Purk­inje fibres and on the hERG potas­sium cur­rent. J. Phar­ma­col Tox­i­col Meth­ods.52: 11522. link


Abstracts/​Posters:

  1. DE KORTE T., GUIL­BOT S., PRINT­EMPS R., HAUTE­FEUILLE L., LE GRAND M., WILBERS R., STEVEN­HAGEN F., DEN HAR­TOGH S.C., NACKEN P., LAN­GEN­BERG K., DUN­SKA M., BRAAM S.R., VLAM­ING M.L.H. Assess­ment of com­pound effects on elec­tro­phys­i­ol­ogy of hiPSC-​derived ven­tric­u­lar car­diomy­ocytes using patch-​clamp and mul­ti­elec­trode array (MEA) analy­sis. SPS meet­ing, Van­cou­ver, Canada, 1821 Sep­tem­ber 2016. link
  2. DUCROQ J., DIDIER H., SAL­VE­TAT C., LE GRAND M. Ex vivo model to inves­ti­gate anti­cancer drug-​induced chronic car­diotox­i­c­ity. SPS meet­ing, Pragues, Czech Repub­lic, 28 Sep­tem­ber to 1 Octo­ber 2015. link
  3. GUIL­BOT S., PRINT­EMPS R., HAUTE­FEUILLE L., DUCROQ J., LE GRAND M. Phar­ma­co­log­i­cal com­par­i­son between human induced pluripo­tent stem cells derived Cor. 4U® ven­tric­u­lar car­diomy­ocytes (hIPSC-​CM) and guinea-​pig ven­tric­u­lar car­diomy­ocytes (GP-​CM). SPS meet­ing, Wash­ing­ton DC, USA, 1922 Octo­bre 2014. link
  4. DUCROQ J., DIDIER H., SAL­VE­TAT C., LE GRAND M. Bleb­bis­tatin alters con­trac­til­ity inde­pen­dently from CaV1.2 chan­nel inhi­bi­tion: can rat and guinea-​pig iso­lated Lan­gen­dorff per­fused heart pre­dict it? SPS meet­ing, Wash­ing­ton DC, USA, 1922 Octo­bre 2014. link
  5. HER­BELLES C., DUCROQ J., DIDIER H., DELPRAT-​ALIES S., TOUTIN A., LE GRAND M., TORD­J­MAN C. Drug accu­mu­la­tion in the heart: An in vitro approach. SPS meet­ing, Rot­ter­dam, Nether­land, 1619 Sep­tem­ber 2013. J. Phar­ma­col Toxi­col Methods., 2014, 70 (3). link
  6. DUCROQ J., DIDIER H., SAL­VE­TAT C., LE GRAND M. Time-​dependent effects of dox­oru­bicin on LVP and ECG para­me­ters in guinea-​pig Lan­gen­dorff per­fused iso­lated heart. SPS meet­ing, Phoenix, USA, 0104 Octo­bre 2012. J. Phar­ma­col Tox­i­col Meth­ods., 2013, 68 (1). link
  7. DUCROQ J., DIDIER H., SAL­VE­TAT C., LE GRAND M. Com­par­i­son of the effects of ver­a­pamil on LVP and ECG para­me­ters between guinea-​pig and rat Lan­gen­dorff per­fused iso­lated heart. SPS meet­ing, Phoenix, USA, 0104 Octo­bre 2012. J. Phar­ma­col Tox­i­col Meth­ods., 2013, 68 (1). link
  8. DUCROQ J., DIDIER H., SAL­VE­TAT C., LE GRAND M. Concentration-​dependent effects of suni­tinib on LVP and ECG para­me­ters in guinea-​pig Lan­gen­dorff per­fused iso­lated heart. SPS meet­ing, Phoenix, USA, 0104 Octo­bre 2012. E J. Phar­ma­col Tox­i­col Meth­ods., 2013, 68 (1). link
  9. DUCROQ J., DIDIER H., SAL­VE­TAT C., LE GRAND M. Detect­ing QT/​APD short­en­ing with rab­bit Purk­inje fibre action poten­tials and guinea-​pig iso­lated per­fused heart. SPS meet­ing, Inns­bruck, Autriche, 1922 Sep­tem­bre 2011. J. Phar­ma­col Tox­i­col Meth­ods., 2012, 66 (2). link
  10. DUCROQ J., PRINT­EMPS R., GUIL­BOT S., SAL­VE­TAT C., LE GRAND M. Mod­els to inves­ti­gate the car­diac effects of ICaL inhi­bi­tion. SPS meet­ing, Boston, USA, 2023 Sep­tem­bre 2010. J. Phar­ma­col Tox­i­col Meth­ods., 2011, 64 (1). link
  11. DUCROQ J., MOHA OU MAATI H., SAL­VE­TAT C., LE GRAND M. Role of IKs in the main­tain­ing of repo­lar­iza­tion reserve dur­ing INaL acti­va­tion: Impli­ca­tion of dox­oru­bicin. SPS meet­ing, Stras­bourg, France, 1518 Sep­tem­bre 2009. J. Phar­ma­col Tox­i­col Meth­ods., 2010, 62 (2).
  12. DUCROQ J., MOHA OU MAATI H., GUIL­BOT S., DILLY S., FAIVRE J.F., BOIS P. LE GRAND M. Acute car­dio­pro­tec­tive effects of dexra­zox­ane against doxorubicin-​induced QT pro­lon­ga­tion is medi­ated by IKs. SPS meet­ing, Madi­son, USA, 2225 Sep­tem­bre 2008. J. Phar­ma­col Tox­i­col Meth­ods., 2009, 60 (2). link
  13. BILLIALD-​DESQUAND S., BRUNET S., HER­BELLES C., DELPY E., DUCROQ J., PRINT­EMPS R., TORD­J­MAN C. Eval­u­a­tion of the car­diac safety of new anti­de­pres­sant drugs : pre­dic­tiv­ity of a com­bined in vitro and in vivo approach. SPS meet­ing, Madi­son, USA, 2225 Sep­tem­bre 2008. J. Phar­ma­col Tox­i­col Meth­ods., 2009, 60 (2). link
  14. MOHA OU MAATI H., DUCROQ J., RIVET J., FAIVRE J.F., LE GRAND M., BOIS P., Cur­cumin blocks the recom­bi­nant human car­diac KCNQ1/​KCNE1 chan­nels (IKs) sta­bly expressed in HEK 293 cells. Con­grès de Phys­i­olo­gie, de Phar­ma­colo­gie et de Thérapeu­tique, Clermont-​Ferrand, France, 911 Avril 2008. Fund. Clin. Phar­ma­col., 2008, 22 (Suppl. 1).
  15. DUCROQ J., STUCKER O., PONS-​HIMBERT C., MER­CADIEU L., DILLY S., CROSS M., LE GRAND M. Acute car­dio­pro­tec­tive effects of dexra­zox­ane dur­ing dox­oru­bicin per­fu­sion in iso­lated guinea-​pig hearts. SPS meet­ing, Edim­bourg, Ecosse, 1821 Sep­tem­bre 2007. J. Phar­ma­col Tox­i­col Meth­ods., 2008, 163. link
  16. DUCROQ J., PRINT­EMPS R., GUIL­BOT S., SAL­VE­TAT C., LE GRAND M. In vitro mod­els to com­plete hERG chan­nel assay in pre­clin­i­cal car­diac safety phar­ma­co­log­i­cal stud­ies. Con­grès de Phys­i­olo­gie, de Phar­ma­colo­gie et de Thérapeu­tique, Toulouse, France, 1113 Avril 2007. Fund. Clin. Phar­ma­col., 2007, 21 (Suppl. 1).
  17. DUCROQ J., PAJEAU P., PRINT­EMPS R., LE GRAND M. Ziprasi­done increases the proar­rhyth­mic risk after a d,l-sotalol pre-​treatment in rab­bit Purk­inje fibres. EPHAR, Porto, Por­tu­gal, 1416 Juin 2004. Fund. Clin. Phar­ma­col., 2004, 18 (Suppl. 1), p.115.
  18. DUCROQ J., PAJEAU P., LE GRAND M. Elec­tro­phys­i­o­log­i­cal effects of ziprazi­done on the action poten­tial para­me­ters of rab­bit Purk­inje fibres. 20ème Con­grès du Groupe de Réflex­ion pour la Recherche Car­dio­vas­cu­laire, Greno­ble, France, 1516 Avril 2003. Arch. Mal. Cœur Vaiss., 2003, 96 p.403.

Pre­sen­ta­tions:

  1. PRINT­EMPS R. Pluri­cytes® ven­tric­u­lar car­diomy­ocytes as a pre­dic­tive tool for pre­clin­i­cal safety assess­ment, com­par­i­son with iso­lated guinea-​pig ven­tric­u­lar car­diomy­ocytes. Plu­ri­omics user meet­ing, Lei­den, The Nether­lands, 25 Novem­ber 2016. pre­sen­ta­tion
  2. PRINT­EMPS R. Human induced pluripo­tent stem cells derived Cor.4U® ven­tric­u­lar car­diomy­ocytes as a pre­dic­tive tool for pre­clin­i­cal safety assess­ment. Axio­gen­e­sis user meet­ing, Cologne, Ger­many, 08 Sep­tem­ber 2016. pre­sen­ta­tion
  3. GUILBOT S. Action poten­tial assay in Cor.4U® cells. Axio­gen­e­sis user meet­ing, Cologne, Ger­many, 06 Novem­ber 2014. pre­sen­ta­tion